These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

233 related articles for article (PubMed ID: 32628531)

  • 1. Clinical Benefits, Harms, and Cost-Effectiveness of Breast Cancer Screening for Survivors of Childhood Cancer Treated With Chest Radiation : A Comparative Modeling Study.
    Yeh JM; Lowry KP; Schechter CB; Diller LR; Alagoz O; Armstrong GT; Hampton JM; Leisenring W; Liu Q; Mandelblatt JS; Miglioretti DL; Moskowitz CS; Oeffinger KC; Trentham-Dietz A; Stout NK
    Ann Intern Med; 2020 Sep; 173(5):331-341. PubMed ID: 32628531
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Breast Cancer Screening Among Childhood Cancer Survivors Treated Without Chest Radiation: Clinical Benefits and Cost-Effectiveness.
    Yeh JM; Lowry KP; Schechter CB; Diller LR; O'Brien G; Alagoz O; Armstrong GT; Hampton JM; Hudson MM; Leisenring W; Liu Q; Mandelblatt JS; Miglioretti DL; Moskowitz CS; Nathan PC; Neglia JP; Oeffinger KC; Trentham-Dietz A; Stout NK
    J Natl Cancer Inst; 2022 Feb; 114(2):235-244. PubMed ID: 34324686
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Tailoring Breast Cancer Screening Intervals by Breast Density and Risk for Women Aged 50 Years or Older: Collaborative Modeling of Screening Outcomes.
    Trentham-Dietz A; Kerlikowske K; Stout NK; Miglioretti DL; Schechter CB; Ergun MA; van den Broek JJ; Alagoz O; Sprague BL; van Ravesteyn NT; Near AM; Gangnon RE; Hampton JM; Chandler Y; de Koning HJ; Mandelblatt JS; Tosteson AN;
    Ann Intern Med; 2016 Nov; 165(10):700-712. PubMed ID: 27548583
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Personalizing mammography by breast density and other risk factors for breast cancer: analysis of health benefits and cost-effectiveness.
    Schousboe JT; Kerlikowske K; Loh A; Cummings SR
    Ann Intern Med; 2011 Jul; 155(1):10-20. PubMed ID: 21727289
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Cost-effectiveness of Breast Cancer Screening With Magnetic Resonance Imaging for Women at Familial Risk.
    Geuzinge HA; Obdeijn IM; Rutgers EJT; Saadatmand S; Mann RM; Oosterwijk JC; Tollenaar RAEM; de Roy van Zuidewijn DBW; Lobbes MBI; van 't Riet M; Hooning MJ; Ausems MGEM; Loo CE; Wesseling J; Luiten EJT; Zonderland HM; Verhoef C; Heijnsdijk EAM; Tilanus-Linthorst MMA; de Koning HJ;
    JAMA Oncol; 2020 Sep; 6(9):1381-1389. PubMed ID: 32729887
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Benefits, harms, and cost-effectiveness of supplemental ultrasonography screening for women with dense breasts.
    Sprague BL; Stout NK; Schechter C; van Ravesteyn NT; Cevik M; Alagoz O; Lee CI; van den Broek JJ; Miglioretti DL; Mandelblatt JS; de Koning HJ; Kerlikowske K; Lehman CD; Tosteson AN
    Ann Intern Med; 2015 Feb; 162(3):157-66. PubMed ID: 25486550
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Breast Cancer Screening Using Mammography, Digital Breast Tomosynthesis, and Magnetic Resonance Imaging by Breast Density.
    Stout NK; Miglioretti DL; Su YR; Lee CI; Abraham L; Alagoz O; de Koning HJ; Hampton JM; Henderson L; Lowry KP; Mandelblatt JS; Onega T; Schechter CB; Sprague BL; Stein S; Trentham-Dietz A; van Ravesteyn NT; Wernli KJ; Kerlikowske K; Tosteson ANA
    JAMA Intern Med; 2024 Oct; 184(10):1222-1231. PubMed ID: 39186304
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Breast Cancer Screening Strategies for Women With ATM, CHEK2, and PALB2 Pathogenic Variants: A Comparative Modeling Analysis.
    Lowry KP; Geuzinge HA; Stout NK; Alagoz O; Hampton J; Kerlikowske K; de Koning HJ; Miglioretti DL; van Ravesteyn NT; Schechter C; Sprague BL; Tosteson ANA; Trentham-Dietz A; Weaver D; Yaffe MJ; Yeh JM; Couch FJ; Hu C; Kraft P; Polley EC; Mandelblatt JS; Kurian AW; Robson ME;
    JAMA Oncol; 2022 Apr; 8(4):587-596. PubMed ID: 35175286
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Tipping the balance of benefits and harms to favor screening mammography starting at age 40 years: a comparative modeling study of risk.
    van Ravesteyn NT; Miglioretti DL; Stout NK; Lee SJ; Schechter CB; Buist DS; Huang H; Heijnsdijk EA; Trentham-Dietz A; Alagoz O; Near AM; Kerlikowske K; Nelson HD; Mandelblatt JS; de Koning HJ
    Ann Intern Med; 2012 May; 156(9):609-17. PubMed ID: 22547470
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Collaborative Modeling of the Benefits and Harms Associated With Different U.S. Breast Cancer Screening Strategies.
    Mandelblatt JS; Stout NK; Schechter CB; van den Broek JJ; Miglioretti DL; Krapcho M; Trentham-Dietz A; Munoz D; Lee SJ; Berry DA; van Ravesteyn NT; Alagoz O; Kerlikowske K; Tosteson AN; Near AM; Hoeffken A; Chang Y; Heijnsdijk EA; Chisholm G; Huang X; Huang H; Ergun MA; Gangnon R; Sprague BL; Plevritis S; Feuer E; de Koning HJ; Cronin KA
    Ann Intern Med; 2016 Feb; 164(4):215-25. PubMed ID: 26756606
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Collaborative Modeling to Compare Different Breast Cancer Screening Strategies: A Decision Analysis for the US Preventive Services Task Force.
    Trentham-Dietz A; Chapman CH; Jayasekera J; Lowry KP; Heckman-Stoddard BM; Hampton JM; Caswell-Jin JL; Gangnon RE; Lu Y; Huang H; Stein S; Sun L; Gil Quessep EJ; Yang Y; Lu Y; Song J; Muñoz DF; Li Y; Kurian AW; Kerlikowske K; O'Meara ES; Sprague BL; Tosteson ANA; Feuer EJ; Berry D; Plevritis SK; Huang X; de Koning HJ; van Ravesteyn NT; Lee SJ; Alagoz O; Schechter CB; Stout NK; Miglioretti DL; Mandelblatt JS
    JAMA; 2024 Jun; 331(22):1947-1960. PubMed ID: 38687505
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Health Benefits and Cost-Effectiveness of Children's Oncology Group Breast Cancer Screening Guidelines for Chest-Irradiated Hodgkin Lymphoma Survivors.
    Wong FL; Lee JM; Leisenring WM; Neglia JP; Howell RM; Smith SA; Oeffinger KC; Moskowitz CS; Henderson TO; Mertens A; Nathan PC; Yasui Y; Landier W; Armstrong GT; Robison LL; Bhatia S
    J Clin Oncol; 2023 Feb; 41(5):1046-1058. PubMed ID: 36265088
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Should women with a BRCA1/2 mutation aged 60 and older be offered intensified breast cancer screening? - A cost-effectiveness analysis.
    Phi XA; Greuter MJW; Obdeijn IM; Oosterwijk JC; Feenstra TL; Houssami N; de Bock GH
    Breast; 2019 Jun; 45():82-88. PubMed ID: 30904701
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Cost-Utility of Early Breast Cancer Surveillance in Survivors of Thoracic Radiation-Treated Adolescent Hodgkin Lymphoma.
    Furzer J; Tessier L; Hodgson D; Cotton C; Nathan PC; Gupta S; Pechlivanoglou P
    J Natl Cancer Inst; 2020 Jan; 112(1):63-70. PubMed ID: 31070751
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Cost-effectiveness of alternating magnetic resonance imaging and digital mammography screening in BRCA1 and BRCA2 gene mutation carriers.
    Cott Chubiz JE; Lee JM; Gilmore ME; Kong CY; Lowry KP; Halpern EF; McMahon PM; Ryan PD; Gazelle GS
    Cancer; 2013 Mar; 119(6):1266-76. PubMed ID: 23184400
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Cost-Effectiveness of Screening Mammography Beyond Age 75 Years : A Cost-Effectiveness Analysis.
    Schousboe JT; Sprague BL; Abraham L; O'Meara ES; Onega T; Advani S; Henderson LM; Wernli KJ; Zhang D; Miglioretti DL; Braithwaite D; Kerlikowske K
    Ann Intern Med; 2022 Jan; 175(1):11-19. PubMed ID: 34807717
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Benefits, harms, and costs for breast cancer screening after US implementation of digital mammography.
    Stout NK; Lee SJ; Schechter CB; Kerlikowske K; Alagoz O; Berry D; Buist DS; Cevik M; Chisholm G; de Koning HJ; Huang H; Hubbard RA; Miglioretti DL; Munsell MF; Trentham-Dietz A; van Ravesteyn NT; Tosteson AN; Mandelblatt JS
    J Natl Cancer Inst; 2014 Jun; 106(6):dju092. PubMed ID: 24872543
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Breast MRI screening for average-risk women: A monte carlo simulation cost-benefit analysis.
    Mango VL; Goel A; Mema E; Kwak E; Ha R
    J Magn Reson Imaging; 2019 Jun; 49(7):e216-e221. PubMed ID: 30632645
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Cost-effectiveness of MRI for breast cancer screening in BRCA1/2 mutation carriers.
    Pataky R; Armstrong L; Chia S; Coldman AJ; Kim-Sing C; McGillivray B; Scott J; Wilson CM; Peacock S
    BMC Cancer; 2013 Jul; 13():339. PubMed ID: 23837641
    [TBL] [Abstract][Full Text] [Related]  

  • 20.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 12.